scholarly journals Congestive kidney failure; recent knowledge and new trends

2021 ◽  
Vol 7 (1) ◽  
pp. e17-e17
Author(s):  
Mehrdad Rabiee Rad ◽  
Ghazal Ghasempour Dabaghi ◽  
Shakiba Hassanzadeh

One of the possible causes of renal failure due to heart failure is congestive kidney failure (CKF). Venous congestion has a key role in the development of renal dysfunction and damage in patients with heart failure. This condition is named congestive nephropathy. In this mini-review the common causes of congestive kidney failure, its pathophysiology, histopathological changes and treatment are discussed.

Heart ◽  
2016 ◽  
Vol 102 (Suppl 6) ◽  
pp. A6.1-A6 ◽  
Author(s):  
Jagdeep Singh ◽  
AH Muhammad Iqbal ◽  
Bayan Soujeri ◽  
Daniel Levin ◽  
Chim C Lang

2021 ◽  
Vol 10 (3) ◽  
pp. 504
Author(s):  
Marina Povar-Echeverría ◽  
Pablo Esteban Auquilla-Clavijo ◽  
Emmanuel Andrès ◽  
Francisco Javier Martin-Sánchez ◽  
María Victoria Laguna-Calle ◽  
...  

Introduction: Inflammation is a fundamental phenomenon in heart failure, but the prognostic or therapeutic role of markers such as interleukin-6 (IL-6) has not yet been clarified. The objective of this study is to describe the clinical profile of patients with elevated IL-6 and determine if they have worse clinical outcomes. Methods: A retrospective c.ohort observational study including 78 patients with heart failure followed up at the Heart Failure Outpatient Clinic of the Internal Medicine Department. IL-6 was determined in all patients, who were then assigned into two groups according to IL-6 level (normal or high). Clinical and prognostic data were collected to determine the differences in both groups. Results: The average age was 79 years, 60% female. A total of 53.8% of the patients had elevated IL-6 (group 2). Patients with elevated IL-6 presented more frequently with anemia mellitus (64.3% vs. 41.7%; p = 0.046), atrial fibrillation (83.3% vs. 61.9% p = 0.036), dyslipidemia (76.2% vs. 58.2%; p = 0.03), higher creatinine levels (1.35 mg/dL vs. 1.08 mg/dL; p = 0.024), lower glomerular filtration rate (43.6 mL/min/m2 vs. 59.9 mL/min/m2; p = 0.007), and anemia 25% vs. 52.4% p = 0.014. The factors independently associated with the increase in IL-6 were anemia 3.513 (1.163–10.607) and renal failure 0.963 (0.936–0.991), p < 0.05. Mortality was higher in the group with elevated IL-6 levels (16% vs. 2%; p = 0.044) with a log-rank p = 0.027 in the Kaplan–Meier curve. Conclusion: Patients with heart failure and elevated IL-6 most often have atrial fibrillation, diabetes mellitus, dyslipidemia, anemia, and renal failure. In addition, mortality was higher and a tendency of higher hospital admission was observed in stable HF patients with elevated IL-6.


1979 ◽  
Vol 17 (12) ◽  
pp. 47-48

Most patients with heart failure and oedema should be treated with thiazide diuretics, which are effective, cheap, safe and easy to use. However, in severe congestive cardiac failure and renal failure haemodynamic and perhaps hormonal disturbances cause salt and water retention which resists thiazide diuretics. Patients with acute pulmonary oedema need a rapid intense diuresis which a thiazide diuretic cannot provide. In these circumstances a drug is needed which can cause the excretion of a substantial fraction of filtered sodium.


Author(s):  
Hai Mai Ba ◽  
Youn-Jung Son ◽  
Kyounghoon Lee ◽  
Bo-Hwan Kim

Heart failure (HF) is a life-limiting illness and presents as a gradual functional decline with intermittent episodes of acute deterioration and some recovery. In addition, HF often occurs in conjunction with other chronic diseases, resulting in complex comorbidities. Hospital readmissions for HF, including emergency department (ED) visits, are considered preventable. Majority of the patients with HF are often discharged early in the recovery period with inadequate self-care instructions. To address these issues, transitional care interventions have been implemented with the common objective of reducing the rate of hospital readmission, including ED visits. However, there is a lack of evidence regarding the benefits and adverse effects of transitional care interventions on clinical outcomes and patient-related outcomes of patients with HF. This integrative review aims to identify the components of transitional care interventions and the effectiveness of these interventions in improving health outcomes of patients with HF. Five databases were searched from January 2000 to December 2019, and 25 articles were included.


2013 ◽  
Vol 34 (suppl 1) ◽  
pp. P645-P645 ◽  
Author(s):  
M. M. Stasiak ◽  
P. Rozentryt ◽  
E. Jankowska ◽  
A. Retwinski ◽  
E. Straburzynska-Migaj ◽  
...  

1987 ◽  
Vol 65 (8) ◽  
pp. 1697-1700 ◽  
Author(s):  
M. Gary Nicholls ◽  
Hamid Ikram ◽  
Ian G. Crozier ◽  
Eric A. Espiner ◽  
Tim G. Yandle

Research on the physiological role of atrial peptides in man is limited, and the potential for these peptides, or more stable analogues, in therapeutics is uncertain. It is clear, however, that plasma levels of immunoreactive atrial natriuretic peptide (IR-ANP) are increased in volunteers taking a high sodium diet, and are elevated in patients with heart failure, chronic renal failure, and primary aldosteronism. There is suggestive evidence that IR-ANP levels are increased also in essential hypertension, although overlap with normotensives is considerable. Injection or infusion of artrial peptides into man results in a diuresis, an increased output of urine electrolytes, a fall in blood pressure and a rise in heart rate, suppression of aldosterone and sometimes of renin also, and stimulation of norepinephrine. In essential hypertensives, urinary effects may be greater than in normotensives. Heart failure patients show a rise in cardiac output and falls in both systemic and pulmonary arterial pressure. Over the next few years and especially if specific antagonists can be developed, the physiologic and pathophysiologic roles of atrial peptides in normal man and in clinical disorders should be clarified. It is possible that stable analogues of atrial peptides will find a place in the treatment of cardiac failure, renal failure, and perhaps hypertension.


Sign in / Sign up

Export Citation Format

Share Document